FOXO4-DRI

Source-reported examples · not treatment recommendations

Amount

250–500 micrograms per day

Frequency

Once daily

Cycle / observation period

8–16 weeks

Route / research model

Subcutaneous

This is a source-reported experimental schedule, not a validated human senolytic treatment. Its human safety and efficacy have not been established by this review.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• FOXO4-DRI is an experimental peptide investigated for disrupting a survival interaction involving FOXO4 and p53 in senescent cells. Selected cell and mouse studies report biological and tissue-level effects. Those findings do not establish a safe human anti-aging treatment or a predictable increase in testosterone. ^{[1] [2]}
• A 2020 study investigated senescent Leydig cells and aged mice. In its cell model, FOXO4-DRI promoted apoptosis through disruption of the FOXO4-p53 interaction. In aged mice, the investigators reported improved testicular conditions and increased testosterone secretion. The full discussion acknowledged that direct elimination of senescent Leydig cells in the aged mice had not been demonstrated. ^[3]
• A 2024 report examined senescent Leydig cells, their secreted factors and a co-culture system. FOXO4-DRI reduced selected senescence-associated secretory signals and improved proliferation of co-cultured cells. In naturally aged mice, the study reported improved sperm quality and spermatogenesis. ^[4]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 14 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original 2017 study
2. Leydig-cell study
3. Original paper
4. Original 2024 report
5. Nature Communications BiologyFurther reading · Listed in reference bibliography.
6. Nature CellNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
7. Aging (Albany NY)Further reading · Listed in reference bibliography.
8. Journal of Cellular and Molecular MedicineFurther reading · Listed in reference bibliography.
9. CellFurther reading · Listed in reference bibliography.
10. PubMedFurther reading · Listed in reference bibliography.
11. MedlinePlusGeneral guidance · Listed in reference bibliography.
12. American Diabetes AssociationFurther reading · Listed in reference bibliography.
13. CDCGeneral guidance · Listed in reference bibliography.
14. CDC (Subcutaneous Injection PDF)General guidance · Listed in reference bibliography.
15. NCBI BookshelfFurther reading · Listed in reference bibliography.
16. PMCFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.